Abstract
The diaminocyclohexane platinum (Pt(DACH)) derivatives ormaplatin and oxaliplatin have caused severe and dose-limiting peripheral sensory neurotoxicity in a clinical trial. We hypothesized that this toxicity could vary in relation to the biotransformation and stereochemistry of these Pt(DACH) derivatives. We prepared pure R,R and S,S enantiomers of ormaplatin (Pt(DACH)Cl4), oxaliplatin (Pt(DACH)oxalato) and their metabolites (Pt(DACH)Cl2 and Pt(DACH)methionine) and assessed their peripheral sensory neurotoxicity and tissue distribution in the rat and in vitro anti-tumour activity in human ovarian carcinoma cell lines. The R,R enantiomers of Pt(DACH)Cl4, Pt(DACH)oxalato and Pt(DACH)Cl2, induced peripheral sensory neurotoxicity at significantly lower cumulative doses (18 +/- 5.7 vs 32 +/- 2.3 micromol kg(-1); P < 0.01) and at earlier times (4 +/- 1 vs 6.7 +/- 0.6 weeks; P = 0.016) during repeat-dose treatment than the S,S enantiomers. Pt(DACH)methionine enantiomers showed no biological activity. There was no difference between Pt(DACH) enantiomers in the platinum concentration in sciatic nerve, dorsal root ganglia, spinal cord, brain or blood at the end of each experiment. Three human ovarian carcinoma cell lines (41 M, 41 McisR and SKOV-3) showed no (or inconsistent) chiral discrimination in their sensitivity to Pt(DACH) enantiomers, whereas two cell lines (CH-1 and CH-1cisR) showed modest enantiomeric selectivity favouring the R,R isomer (more active). In conclusion, Pt(DACH) derivatives exhibit enantiomeric-selective peripheral sensory neurotoxicity during repeated dosing in rats favouring S,S isomers (less neurotoxic). They exhibited less chiral discrimination in their accumulation within peripheral nerves and in vitro anti-tumour activity.
Full text
PDF








Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Anderson W. K., Quagliato D. A., Haugwitz R. D., Narayanan V. L., Wolpert-DeFilippes M. K. Synthesis, physical properties, and antitumor activity of tetraplatin and related tetrachloroplatinum(IV) stereoisomers of 1,2-diaminocyclohexane. Cancer Treat Rep. 1986 Aug;70(8):997–1002. [PubMed] [Google Scholar]
- Burchenal J. H., Kalaher K., O'Toole T., Chisholm J. Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia. Cancer Res. 1977 Sep;37(9):3455–3457. [PubMed] [Google Scholar]
- Carfagna P. F., Poma A., Wyrick S. D., Holbrook D. J., Chaney S. G. Comparisons of tetrachloro(d,l-trans)1,2-diaminocyclohexane-platinum(IV) biotransformations in the plasma of Fischer 344 rats at therapeutic and toxic doses. Cancer Chemother Pharmacol. 1991;27(5):335–341. doi: 10.1007/BF00688854. [DOI] [PubMed] [Google Scholar]
- Cavaletti G., Tredici G., Marmiroli P., Petruccioli M. G., Barajon I., Fabbrica D. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol. 1992;84(4):364–371. doi: 10.1007/BF00227662. [DOI] [PubMed] [Google Scholar]
- Chaney S. G., Wyrick S., Till G. K. In vitro biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma. Cancer Res. 1990 Aug 1;50(15):4539–4545. [PubMed] [Google Scholar]
- Clarkson T. W. Molecular and ionic mimicry of toxic metals. Annu Rev Pharmacol Toxicol. 1993;33:545–571. doi: 10.1146/annurev.pa.33.040193.002553. [DOI] [PubMed] [Google Scholar]
- De Koning P., Neijt J. P., Jennekens F. G., Gispen W. H. Evaluation of cis-diamminedichloroplatinum (II) (cisplatin) neurotoxicity in rats. Toxicol Appl Pharmacol. 1987 Jun 15;89(1):81–87. doi: 10.1016/0041-008x(87)90178-5. [DOI] [PubMed] [Google Scholar]
- Drayer D. E. Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview. Clin Pharmacol Ther. 1986 Aug;40(2):125–133. doi: 10.1038/clpt.1986.150. [DOI] [PubMed] [Google Scholar]
- Eastman A. Glutathione-mediated activation of anticancer platinum(IV) complexes. Biochem Pharmacol. 1987 Dec 1;36(23):4177–4178. doi: 10.1016/0006-2952(87)90581-8. [DOI] [PubMed] [Google Scholar]
- Extra J. M., Espie M., Calvo F., Ferme C., Mignot L., Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 1990;25(4):299–303. doi: 10.1007/BF00684890. [DOI] [PubMed] [Google Scholar]
- Gibbons G. R., Wyrick S., Chaney S. G. Rapid reduction of tetrachloro(D,L-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium. Cancer Res. 1989 Mar 15;49(6):1402–1407. [PubMed] [Google Scholar]
- Gregg R. W., Molepo J. M., Monpetit V. J., Mikael N. Z., Redmond D., Gadia M., Stewart D. J. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol. 1992 May;10(5):795–803. doi: 10.1200/JCO.1992.10.5.795. [DOI] [PubMed] [Google Scholar]
- Hills C. A., Kelland L. R., Abel G., Siracky J., Wilson A. P., Harrap K. R. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer. 1989 Apr;59(4):527–534. doi: 10.1038/bjc.1989.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kelland L. R., Mistry P., Abel G., Loh S. Y., O'Neill C. F., Murrer B. A., Harrap K. R. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res. 1992 Jul 15;52(14):3857–3864. [PubMed] [Google Scholar]
- Kido Y., Khokhar A. R., Siddik Z. H. Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines. Anticancer Drugs. 1993 Apr;4(2):251–258. doi: 10.1097/00001813-199304000-00018. [DOI] [PubMed] [Google Scholar]
- Lévi F., Misset J. L., Brienza S., Adam R., Metzger G., Itzakhi M., Caussanel J. P., Kunstlinger F., Lecouturier S., Descorps-Declère A. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer. 1992 Feb 15;69(4):893–900. doi: 10.1002/1097-0142(19920215)69:4<893::aid-cncr2820690410>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
- Mauldin S. K., Gibbons G., Wyrick S. D., Chaney S. G. Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line. Cancer Res. 1988 Sep 15;48(18):5136–5144. [PubMed] [Google Scholar]
- McKeage M. J., Boxall F. E., Jones M., Harrap K. R. Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat. Cancer Res. 1994 Feb 1;54(3):629–631. [PubMed] [Google Scholar]
- Pendyala L., Creaven P. J. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993 Dec 15;53(24):5970–5976. [PubMed] [Google Scholar]
- Petros W. P., Chaney S. G., Smith D. C., Fangmeier J., Sakata M., Brown T. D., Trump D. L. Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial. Cancer Chemother Pharmacol. 1994;33(4):347–354. doi: 10.1007/BF00685911. [DOI] [PubMed] [Google Scholar]
- Schilder R. J., LaCreta F. P., Perez R. P., Johnson S. W., Brennan J. M., Rogatko A., Nash S., McAleer C., Hamilton T. C., Roby D. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res. 1994 Feb 1;54(3):709–717. [PubMed] [Google Scholar]
- Siddik Z. H., Jones M., Boxall F. E., Harrap K. R. Comparative distribution and excretion of carboplatin and cisplatin in mice. Cancer Chemother Pharmacol. 1988;21(1):19–24. doi: 10.1007/BF00262732. [DOI] [PubMed] [Google Scholar]
- Siddik Z. H., al-Baker S., Burditt T. L., Khokhar A. R. Differential antitumor activity and toxicity of isomeric 1,2-diaminocyclohexane platinum (II) complexes. J Cancer Res Clin Oncol. 1993;120(1-2):12–16. doi: 10.1007/BF01200718. [DOI] [PubMed] [Google Scholar]
- Sorenson C. M., Barry M. A., Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst. 1990 May 2;82(9):749–755. doi: 10.1093/jnci/82.9.749. [DOI] [PubMed] [Google Scholar]
- Terheggen P. M., van der Hoop R. G., Floot B. G., Gispen W. H. Cellular distribution of cis-diamminedichloroplatinum(II)-DNA binding in rat dorsal root spinal ganglia: effect of the neuroprotecting peptide ORG.2766. Toxicol Appl Pharmacol. 1989 Jun 15;99(2):334–343. doi: 10.1016/0041-008x(89)90015-x. [DOI] [PubMed] [Google Scholar]
- Thompson S. W., Davis L. E., Kornfeld M., Hilgers R. D., Standefer J. C. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer. 1984 Oct 1;54(7):1269–1275. doi: 10.1002/1097-0142(19841001)54:7<1269::aid-cncr2820540707>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
- Vollano J. F., Al-Baker S., Dabrowiak J. C., Schurig J. E. Comparative antitumor studies on platinum(II) and platinum(IV) complexes containing 1,2-diaminocyclohexane. J Med Chem. 1987 Apr;30(4):716–719. doi: 10.1021/jm00387a023. [DOI] [PubMed] [Google Scholar]
- Wilkoff L. J., Dulmadge E. A., Trader M. W., Harrison S. D., Jr, Griswold D. P., Jr Evaluation of trans-tetrachloro-1,2-diaminocyclohexane platinum (IV) in murine leukemia L1210 resistant and sensitive to cis-diamminedichloroplatinum (II). Cancer Chemother Pharmacol. 1987;20(2):96–100. doi: 10.1007/BF00253961. [DOI] [PubMed] [Google Scholar]